Mannatech Inc.

MTEX

Nasdaq; healthcare; SIC 2833, Medicinal Chemicals & Botanical Products; CIK 0001056358

B

second fifth of 367 graded peers in healthcare

rank 96 of 367; percentile 26.0; sampling error 2.5 points; lower is stronger

A B C D E

B, the elk



Scoreboard

Profitability	A percentile 10.8
Solvency	C percentile 45.8
Growth and financing	D percentile 63.3
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $30.0M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	late filer; fortress balance sheet not computable: distress
Inputs computable	9 of 14
Graded from	filings received through Apr 15, 2026 214 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026
Last close	$8.13 2026-11-06; market equity $15.7M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Apr 15, 2026

Mannatech, Incorporated ("Mannatech" or the "Company") is a global wellness solution provider, which was incorporated and began operations in November 1993. We develop and sell innovative, high quality, proprietary nutritional supplements, skin care and anti-aging products, and weight-management products that target optimal health and wellness.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 10.8						
Gross profitability	269.9%	32.3%		0.0	365	2025-12-31
Return on invested capital	not computable	9.3%				
a prior annual debt, equity, and cash observation is required						
Accruals ratio	(37.1%)	(6.6%)		10.9	799	2025-12-31
Gross margin stability, five years	1.4 pts	2.8 pts		21.6	242	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Solvency, sleeve percentile 45.8						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(1.37)	(0.31)	43.0	743	2025-12-31	
Net debt to EBITDA	(5.16x)	1.82x	6.8	75	2025-12-31	
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	1.10x	2.96x	87.6	825	2025-12-31	
Growth and financing, sleeve percentile 63.3						
Revenue growth, three-year compound	(7.7%)	10.1%	83.9	411	2025-12-31	
Free cash flow growth, three-year compound	not computable	11.0%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	(15.2%)	2.3%	76.9	693	2025-12-31	
Net share issuance, one year	1.5%	2.4%	29.2	627	2026-04-08	

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Fortress balance sheet	cash minus debt is 3,435,000 USD; Altman Z is not used

Among 367 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
91	Sarepta Therapeutics, Inc. (SRPT)	24.6	B	
92	Pulmonx Corp. (LUNG)	24.9	B	fortress balance sheet
93	Rhythm Pharmaceuticals, Inc. (RYTM)	25.1	B	short runway
94	GE HealthCare Technologies Inc. (GEHC)	25.4	B	
95	4D Molecular Therapeutics, Inc. (FDMT)	25.7	B	dilution, short runway
96	Mannatech Inc. (MTEX)	26.0	B	late filer, fortress balance sheet
97	Phibro Animal Health Corp. (PAHC)	26.2	B	
98	Sensus Healthcare, Inc. (SRTS)	26.5	B	
99	Staar Surgical Co. (STAA)	26.8	B	
100	Travere Therapeutics, Inc. (TVTX)	27.0	B	
101	Tela Bio, Inc. (TELA)	27.3	B	fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(29.5%)	(1.5%)	30
Distance from 52-week high	(36.0%)	(32.0%)	43
EBIT to enterprise value	(4.5%)	(1.8%)	44
Free cash flow yield	(35.5%)	(1.0%)	17
Book value to price	0.43	0.29	62
Sales to price	8.88	0.29	99
Composite equity issuance, five years	(19.6%)	19.1%	9
Relative strength against the sector, log excess return	(0.52)	(0.18)	30

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$5.4M
Operating cash flow, four quarters	-$204,000
Months of runway	318.8
Days since last periodic filing	3 (10-Q received Nov 12, 2026)
Median daily dollar volume, 63 sessions	$184,555

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$81.0M	2025-12-31	2026-04-15	10-K	26-012430
2	assets	us-gaap:Assets	$30.0M	2025-12-31	2026-04-15	10-K	26-012430
3	operating income	us-gaap:OperatingIncomeLoss	-$426,000	2025-12-31	2026-04-15	10-K	26-012430
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$2.9M	2025-12-31	2026-04-15	10-K	26-012430
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$12.3M	2025-12-31	2026-04-15	10-K	26-012430
6	total debt	us-gaap:LongTermDebt	$2.8M	2025-12-31	2026-04-15	10-K	26-012430
7	book equity	us-gaap:StockholdersEquity	-$5.2M	2025-12-31	2026-04-15	10-K	26-012430
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$6.2M	2025-12-31	2026-04-15	10-K	26-012430
9	net income	us-gaap:NetIncomeLoss	-$15.2M	2025-12-31	2026-04-15	10-K	26-012430
10	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$3.0M	2025-12-31	2026-04-15	10-K	26-012430
11	assets	us-gaap:Assets	$36.1M	2024-12-31	2026-04-15	10-K	26-012430
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$108.0M	2025-12-31	2026-04-15	10-K	26-012430
13	gross profit	us-gaap:GrossProfit	$91.5M	2024-12-31	2026-04-15	10-K	26-012430
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$117.9M	2024-12-31	2026-04-15	10-K	26-012430
15	gross profit	us-gaap:GrossProfit	$102.9M	2023-12-31	2025-03-26	10-K	25-000018
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$132.0M	2023-12-31	2025-03-26	10-K	25-000018
17	gross profit	us-gaap:GrossProfit	$104.1M	2022-12-31	2024-03-28	10-K	24-000026
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$137.2M	2022-12-31	2024-03-28	10-K	24-000026

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	gross profit	us-gaap:GrossProfit	$125.6M	2021-12-31	2023-03-17	10-K	23-000022
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$159.8M	2021-12-31	2023-03-17	10-K	23-000022
21	current assets	us-gaap:AssetsCurrent	$20.6M	2025-12-31	2026-04-15	10-K	26-012430
22	current liabilities	us-gaap:LiabilitiesCurrent	$18.7M	2025-12-31	2026-04-15	10-K	26-012430
23	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$14.0M	2025-12-31	2026-04-15	10-K	26-012430
24	liabilities	us-gaap:Liabilities	$35.2M	2025-12-31	2026-04-15	10-K	26-012430
25	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$1.1M	2025-12-31	2026-04-15	10-K	26-012430
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.4M	2025-12-31	2026-04-15	10-K	26-012430
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.3M	2024-12-31	2026-04-15	10-K	26-012430
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$297,000	2024-12-31	2026-04-15	10-K	26-012430
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$2.4M	2023-12-31	2025-03-26	10-K	25-000018
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$748,000	2023-12-31	2025-03-26	10-K	25-000018
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$2.6M	2022-12-31	2024-03-28	10-K	24-000026
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.1M	2022-12-31	2024-03-28	10-K	24-000026
33	current assets	us-gaap:AssetsCurrent	$26.1M	2024-12-31	2026-04-15	10-K	26-012430
34	current liabilities	us-gaap:LiabilitiesCurrent	$20.9M	2024-12-31	2026-04-15	10-K	26-012430
35	assets	us-gaap:Assets	$41.2M	2023-12-31	2025-03-26	10-K	25-000018
36	assets	us-gaap:Assets	$49.1M	2022-12-31	2024-03-28	10-K	24-000026
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,929,670	2026-04-08	2026-04-15	10-K	26-012430
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,900,930	2025-03-18	2025-03-26	10-K	25-000018

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.